Scientific Plenary Session 4
EXPECTED ROLE OF INTEGRATED BIOMARKERS IN
THE DEVELOPMENT OF NEW DRUGS
Concensus Round Table Organized by the Food And Drug Administration (FDA)
(Supported by University of Washington and
Giovanni Lorenzini Medical Science Foundation)
Chairs: Federico Goodsaid (Silver Spring, MD, USA)
Santica Marcovina (Seattle, WA, USA)
3:30pm
ROADMAP TO REGULATORY APPROVAL OF BIOMARKERS
Federico Goodsaid (Silver Spring, MD, USA)
3:50pm
CURRENT STATUS OF INTEGRATED BIOMARKERS IN DRUG DEVELOPMENT
Wolfgang Koenig (Ulm, Germany)
4:10pm
NOVEL INTEGRATED BIOIMAGING AND BIOCHEMICAL
BIOMARKERS FOR AN EMERGING CARDIOVASCULAR TARGET
Jean-Claude Tardif (Montreal, Canada)
4:30pm
CAROTID IMT: CRITERIA AND CURRENT EVIDENCE FOR SURROGACY AS A
BIOMARKER FOR CARDIOVASCULAR EVENTS IN CLINICAL TRIALS
Daniel O'Leary (Boston, MA, USA)
4:50pm
PLAQUE BIOMARKERS IN DRUG DEVELOPMENT FOR ATHEROSCLEROSIS
Eric Hailman (Rahway, NJ, USA)
5:10pm
IMPACT OF MIDREGIONAL PRO-ADRENOMEDULLIN FOR PREDICTION
OF CARDIOVASCULAR EVENTS IN THE ATHEROGENE STUDY
Philipp Wild (Mainz, Germany)
5:30pm
End of the Session